Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single non-curative dose (10 Gy), resulting in a growth delay with a subsequent regrowth of the tumours. In the rhEPO-treated group, the growth delay lasted significantly longer (9.5 days vs. 4.5 days) and the regrowth was slower (6.0 days vs. 4.1 days) compared with the anaemic group. These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.

• Publication year

  1998

• Venue

  British Journal of Cancer

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.1998.572PMID 9743294PMCID 2062974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma

  2004cited by this paper
• Significance of Hemoglobin Concentration for Treatment Outcome

  2000cited by this paper
• Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.

  1998cited by this paper
• Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats.

  1996cited by this paper
• Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion.

  1995cited by this paper
• The role of tumor volume in 'reoxygenation' upon cyclophosphamide treatment.

  1995influential reference
• Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.

  1995cited by this paper
• Recombinant human erythropoietin and the anemia of cancer.

  1994cited by this paper
• The use of recombinant human erythropoietin to prevent carboplatin‐induced anemia

  1993cited by this paper
• Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats.

  1993influential reference
• Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.

  1993cited by this paper
• The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

  1993influential reference
• Erythropoietin increases hemoglobin in cancer patients during radiation therapy.

  1993cited by this paper
• Blood Transfusion in Patients Receiving Radical Radiotherapy: A Reappraisal

  1993cited by this paper
• Br. J. Cancer

  1991cited by this paper
• Chronic anaemia, hyperbaric oxygen and tumour radiosensitivity.

  1990cited by this paper
• Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

  1989cited by this paper
• Haematological toxicity of carboplatin in rats.

  1987influential reference
• Effect of anemia on tumor radiosensitivity under normo and hyperbaric conditions.

  1987influential reference
• The effect of alterations in haematocrit on tumour sensitivity to X-rays.

  1984influential reference
• Definitive evidence for hypoxic cells influencing cure in cancer therapy.

  1978cited by this paper
• The effect of anaemia on the fraction of hypoxic cells in an experimental tumour.

  1971cited by this paper
• Effect of Induced Host Anaemia on the Viability and Radiosensitivity of Murine Malignant Cells in vivo

  1971cited by this paper
• Tumor growth and cell kinetics in chronically hypoxic animals.

  1970cited by this paper

• Repurposing radiosensitising medicines for radiotherapy: an overview

  2024cites this paper
• Therapeutic Modification of Hypoxia.

  2021cites this paper
• From Anemia to Erythropoietin Resistance in Head and Neck Squamous Cell Carcinoma Treatment: A Carousel Driven by Hypoxia

  2020cites this paper
• Hämatologische Toxizität der Strahlentherapie und Management

  2020cites this paper
• Serum erythropoietin levels, breast cancer and breast cancer-initiating cells

  2019cites this paper
• Clinicopathological significance of Epo, EpoR, Ki-67 and Bax expression in colorectal cancer

  2018cites this paper
• 2 Animal Models of Hematopoietic Growth Factor Perturbations in Physiology and Pathology

  2017cites this paper
• Mitochondrial dynamics in the radiation response of cancer cells

  2017cites this paper
• In Regard to Shenouda et al.

  2015cites this paper
• 9.08 – Tumor Hypoxia

  2014cites this paper
• 34 – Disorders of Blood Cell Production in Clinical Oncology

  2014cites this paper
• Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.

  2014cites this paper
• Hypoxia and Radiation Therapy

  2014cites this paper
• Human Papillomavirus (HPV) Infection And Erythropoietin Receptors (EpoR) Expression As Prognostic Indicators In Oropharyngeal Cancer

  2013cites this paper
• Erythropoietin use in CKD patients with cancer: to tread with caution?

  2013cites this paper
• Chapter 3 – Dose-Response Modifiers in Radiation Therapy

  2012cites this paper
• Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

  2012cites this paper
• The Clinical Value of Erythropoietin in Patients with Cancer

  2012cites this paper
• The effect of erythropoietin on normal and neoplastic cells

  2012cites this paper
• Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy

  2012cites this paper
• Presence of anemia and poor prognostic factors in patients with endometrial carcinoma.

  2012cites this paper
• Novel radioimmunotherapy for lymphoma and solid tumours both as a single agent and in combination with the vascular disrupting agents

  2011cites this paper
• Hematologic Support of the Patient with Malignancy

  2011cites this paper
• Randomized controlled trials of the erythroid-stimulating agents in cancer patients.

  2011cites this paper
• High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma.

  2011cites this paper
• Erythropoietin.

  2011cites this paper
• Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinum-based chemotherapy.

  2011cites this paper
• Endogenous Myoglobin in Breast Cancer Is Hypoxia-inducible by Alternative Transcription and Functions to Impair Mitochondrial Activity

  2011cites this paper
• Epo delivery by genetically engineered C2C12 myoblasts immobilized in microcapsules.

  2010cites this paper
• Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype

  2010cites this paper
• Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited

  2010cites this paper
• Prevalence and incidence of anemia in Thai patients with gynecologic cancer.

  2010cites this paper
• Impact on Radiotherapy

  2010cites this paper
• [Erythropoietin and radiotherapy].

  2010cites this paper
• Twist and Shout: One Decade of Meta-Analyses of Erythropoiesis-Stimulating Agents in Cancer Patients

  2010cites this paper
• Erythropoietic‐stimulating agents: the cancer progression controversy and collateral damage to the blood supply

  2009cites this paper
• Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.

  2009cites this paper
• Molecular pathology of tumor metastasis III

  2009cites this paper
• Significance of the Tumour Microenvironment in Radiotherapy

  2009cites this paper
• Biological functions and therapeutic use of erythropoiesis‐stimulating agents: perplexities and perspectives

  2009cites this paper
• How Might ESAs Alter Cancer Biology , Response to Treatment , or Survival ?

  2009cites this paper
• Anemia and Red Cell Factors

  2008cites this paper
• Tumor hypoxia and therapeutic resistance

  2008cites this paper
• Erythropoietin in cancer: the new face of an old friend.

  2008cites this paper
• Treatment of anemia with rhEPO in radiation oncology

  2008cites this paper
• The erythropoietin receptor in normal and cancer tissues.

  2008cites this paper
• The effect of rhEPO on survival in anemic cancer patients

  2008cites this paper
• Erythropoiesis-Stimulating Agents and the Practice of Gynecologic Oncology

  2008cites this paper
• Pharmacodynamic model for chemotherapy-induced anemia in rats

  2008cites this paper
• [Erythropoietin--use in hematologic oncology and radiotherapy].

  2008cites this paper
• rhEPO in anemic patients with solid tumors and chemotherapy — efficacy and safety

  2008cites this paper
• Relationship between hemoglobin levels and tumor oxygenation

  2008cites this paper
• Erythropoiesis-Stimulating Agents: Favorable Safety Profile When Used as Indicated

  2008cites this paper
• Significance of anemia in cancer chemotherapy

  2008cites this paper
• Risks and benefits of erythropoiesis-stimulating agents in cancer management.

  2007cites this paper
• Erythropoetin in der Strahlentherapie

  2007cites this paper
• Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

  2007cites this paper
• Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.

  2007cites this paper
• Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels

  2007cites this paper
• BACKGROUND INFORMATION FOR ONCOLOGIC DRUGS ADVISORY COMMITTEE

  2007cites this paper
• Inhibition of x-irradiation-enhanced locomotor recovery after spinal cord injury by hyperbaric oxygen or the antioxidant nitroxide tempol.

  2007cites this paper
• Anemia correction in malignancy management: threat or opportunity?

  2007cites this paper
• Effects of recombinant erythropoietin on breast cancer-initiating cells.

  2007cites this paper
• Expression and function of erythropoietin receptors in tumors

  2007cites this paper
• The Necessity of Weekly Hemoglobin Level Monitoring in Cervical Cancer Patients Receiving Radiotherapy

  2007cites this paper
• Recombinant human erythropoietin in the treatment of nonrenal anemia

  2006cites this paper
• The Effect of Darbepoetin Alfa on Growth, Oxygenation and Radioresponsiveness of a Breast Adenocarcinoma

  2006cites this paper
• Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.

  2006cites this paper
• Oncological implications of hypoxia inducible factor-1α (HIF-1α) expression

  2006cites this paper
• To give or not to give recombinant EPO to anemia endangered cancer patients.

  2006cites this paper
• Erythropoietin Biology in Cancer

  2006cites this paper
• Hämatopoetische Wachstumsfaktoren in der Strahlentherapie

  2006cites this paper
• Postoperative therapy modalities for cervical carcinoma.

  2006cites this paper
• Cancer-related anemia and recombinant human erythropoietin—an updated overview

  2006cites this paper
• Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells

  2006cites this paper
• Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better?

  2006cites this paper
• Epoetin beta in oncology: examining the current evidence.

  2006cites this paper
• [The aftercare principle for metastasizing prostate cancer. Few diagnostics, much support].

  2005cites this paper
• Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma

  2005cites this paper
• The development of erythropoietic agents in oncology

  2005cites this paper
• Erythropoietin in cancer treatment: Considerations about Henke’s article

  2005cites this paper
• Das Nachsorgeprinzip beim metastasierten Prostatakarzinom

  2005cites this paper
• [Erythropoietin and cancer-related anaemia. Light and shade].

  2005cites this paper
• Cancer patient survival and erythropoietin.

  2005cites this paper
• Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life

  2005cites this paper
• Impact of anemia in patients with head and neck cancer treated with radiation therapy

  2005cites this paper
• The impact of anaemia on outcome in cancer.

  2005cites this paper
• Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

  2005cites this paper
• Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia.

  2005cites this paper
• Hypoxia and anaemia in patients with cancer of the uterine cervix

  2005cites this paper
• Erythropoietin in cancer treatment: considerations about Henke's article.

  2005cites this paper
• External radiotherapy and anaemia treatment: state of the art.

  2005cites this paper
• Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy

  2005cites this paper
• Ruolo Dell'eritropoietina Nel Paziente Oncologico: Revisione Critica Della Letteratura

  2005cites this paper
• Beyond Anaemia Management: Evolving Role of Erythropoietin Therapy in Neurological Disorders, Multiple Myeloma and Tumour Hypoxia Models

  2005cites this paper
• Blood Transfusion Requirements for Patients With Sarcomas Undergoing Combined Radio- and Chemotherapy

  2005cites this paper
• Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

  2005cites this paper
• Eritropoyetina en la anemia del paciente oncológico. Luces y sombras

  2005cites this paper
• Animal Models of Hematopoietic Growth Factor Perturbations in Physiology and Pathology

  2004cites this paper
• Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.

  2004cites this paper